Adicet Bio, Inc. Operating Lease Cost
Adicet Bio, Inc. (ACET) reported Operating Lease Cost of $922.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- Adicet Bio, Inc. operating lease, cost for the quarter ending 2026-06-30 was $922.00K, a 24.92% decline year-over-year.
- Adicet Bio, Inc. operating lease, cost for the quarter ending 2026-03-31 was $837.00K, a 26.51% decline year-over-year.
- Adicet Bio, Inc. operating lease, cost for the quarter ending 2025-12-31 was $907.00K, a 21.61% decline year-over-year.
- Adicet Bio, Inc. operating lease, cost for the quarter ending 2025-09-30 was $949.00K, a 16.75% decline year-over-year.
- Adicet Bio, Inc. operating lease, cost for fiscal 2025 was $4.21M, a 7.68% decline from fiscal 2024.
- Adicet Bio, Inc. operating lease, cost for fiscal 2024 was $4.56M, a 1.04% increase from fiscal 2023.
- Adicet Bio, Inc. operating lease, cost for fiscal 2023 was $4.51M, a 0.04% increase from fiscal 2022.
- Adicet Bio, Inc. operating lease, cost for fiscal 2022 was $4.51M, a 5.28% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $922.00K 10-Q · filed 2026-08-05 | $1.80M 10-Q · filed 2026-08-05 | $2.67M derived: sum of 3 quarters · filed 2026-08-05 | $3.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $837.00K 10-Q · filed 2026-05-13 | $1.74M derived: sum of 2 quarters · filed 2026-05-13 | $2.69M derived: sum of 3 quarters · filed 2026-05-13 | $3.92M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $907.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.86M derived: sum of 2 quarters · filed 2026-03-12 | $3.08M derived: sum of 3 quarters · filed 2026-03-12 | $4.21M 10-K · filed 2026-03-12 |
| 2025-09-30 | $949.00K 10-Q · filed 2025-11-05 | $2.18M derived: sum of 2 quarters · filed 2025-11-05 | $3.30M 10-Q · filed 2025-11-05 | $4.47M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $1.23M 10-Q · filed 2025-08-07 | $2.40M 10-Q · filed 2025-08-07 | $3.52M derived: sum of 3 quarters · filed 2026-03-12 | $4.66M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $1.14M 10-Q · filed 2025-05-06 | $2.30M derived: sum of 2 quarters · filed 2026-03-12 | $3.44M derived: sum of 3 quarters · filed 2026-03-12 | $4.58M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.30M derived: sum of 2 quarters · filed 2026-03-12 | $3.44M derived: sum of 3 quarters · filed 2026-03-12 | $4.56M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.14M 10-Q · filed 2024-11-06 | $2.28M derived: sum of 2 quarters · filed 2024-11-06 | $3.40M 10-Q · filed 2024-11-06 | $1.14B derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | $1.14M 10-Q · filed 2024-08-13 | $2.30M 10-Q · filed 2024-08-13 | $1.14B derived: sum of 3 quarters · filed 2025-03-06 | $1.14B derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | $1.14B 10-Q · filed 2024-05-14 | $1.14B derived: sum of 2 quarters · filed 2025-03-06 | $1.14B derived: sum of 3 quarters · filed 2025-03-06 | $1.14B derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.35M derived: sum of 2 quarters · filed 2025-03-06 | $3.44M derived: sum of 3 quarters · filed 2025-03-06 | $4.51M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.14M 10-Q · filed 2023-11-08 | $2.23M derived: sum of 2 quarters · filed 2023-11-08 | $3.30M 10-Q · filed 2023-11-08 | $6.77M derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | $1.09M 10-Q · filed 2023-08-09 | $2.20M 10-Q · filed 2023-08-09 | $5.63M derived: sum of 3 quarters · filed 2024-03-19 | $5.70M derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | $1.14M 10-Q · filed 2023-05-09 | $4.54M derived: sum of 2 quarters · filed 2024-03-19 | $4.61M derived: sum of 3 quarters · filed 2024-03-19 | $4.64M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.47M derived: sum of 2 quarters · filed 2024-03-19 | $3.50M derived: sum of 3 quarters · filed 2024-03-19 | $4.51M 10-K · filed 2024-03-19 |
| 2022-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $101.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.11M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.04M 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | $1.01M 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $4.28M 10-K · filed 2023-03-15 | |||
| 2020-12-31 | $894.00K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |